Compare SpaceX (SPCX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SpaceX vs TG Therapeutics Inc — how do they compare? SpaceX trades at $123.46 (market cap $1.58T), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: SpaceX is far larger — about 191.3× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, SpaceX nearer its low. Which is the better fit depends on your goals.
| SPCX | TGTX | |
|---|---|---|
Market Cap | $1.58T | $8.26B |
Sector | Technology | Health |
52-Week High | $202.09 | $59.06 |
52-Week Low | $119.85 | $26.39 |
Enterprise Value | $1.59T | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPCX trades at $123.46, down 0.43% amid bearish technical signals despite recent rebound attempts. The company shows strong revenue growth with $18.67B in 2025 but faces significant profitability challenges with a -45% net income margin. Analyst consensus remains strongly bullish with a $237.78 price target, though upcoming August earnings and share unlock events create near-term uncertainty.
While SpaceX maintains strong revenue momentum and AI infrastructure potential, investors face substantial risks from persistent losses, high valuations, and imminent share dilution. The stock's technical weakness contrasts with Wall Street's long-term optimism, creating a high-risk, high-reward scenario dependent on upcoming earnings execution and competitive positioning.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SpaceX
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
